23. The method of claim 1, wherein said polypeptide comprises protein S Gla domain and protein S EGF domain.

24. The method of claim 1, wherein said polypeptide comprises prothrombin Gla domain.

25. The method of claim 1, wherein said polypeptide comprises prothrombin Gla domain plus prothrombin Kringle domain.

26. The method of claim 1, wherein said polypeptide comprises protein Z Gla domain.

27. The method of claim 1, wherein said polypeptide comprises protein Z Gla domain plus prothrombin Kringle domain.

28. The method of claim 1, wherein said polypeptide comprises Factor VII Gla domain.

29. The method of claim 1, wherein said polypeptide comprises Factor VII Gla domain plus prothrombin Kringle domain.

30. The method of claim 1, wherein said polypeptide further comprises an antibody Fc region.

31. A method of treating cancer in a subject comprising administering to said subject an isolated polypeptide comprising a gamma-carboxyglutamic-acid (Gla) domain and lacking a protease or hormone-binding domain, wherein said polypeptide is linked to a therapeutic payload.

32. The method of claim 31, wherein said therapeutic payload is a chemotherapeutic, a radiotheraputic or a toxin.

33. The method of claim 31, where said cancer is breast cancer, brain cancer, stomach cancer, lung cancer, prostate cancer, ovarian cancer, testicular cancer, colon cancer, skin cancer, rectal cancer, cervical cancer, uterine cancer, liver cancer, pancreatic cancer, head & neck cancer or esophageal cancer.

34. A method of treating a viral diease in a subject comprising administering to said subject an isolated polypeptide comprising a gamma-carboxyglutamic-acid (Gla) domain and lacking a protease or hormone-binding domain, wherein said polypeptide is linked to an anti-viral agent.

35. The method of claim 34, wherein said viral disease is influenza, human immunodeficiency virus, dengue virus, West Nile virus, smallpox virus, respiratory syncytial virus, Korean hemorrhagic fever virus, chickenpox, varicella zoster virus, herpes simplex virus 1 or 2, Epstein-Barr virus, Marburg virus, hantavirus, yellow fever virus, hepatitis A, B, C or E, Ebola virus, human papilloma virus, rhinovirus, Coxsackie virus, polio virus, measles virus, rubella virus, rabies virus, Newcastle disease virus, rotavirus, HTLV-1 and -2.

23. The method of claim 1, wherein said polypeptide comprises protein S Gla domain and protein S EGF domain.

24. The method of claim 1, wherein said polypeptide comprises prothrombin Gla domain.

25. The method of claim 1, wherein said polypeptide comprises prothrombin Gla domain plus prothrombin Kringle domain.

26. The method of claim 1, wherein said polypeptide comprises protein Z Gla domain.

27. The method of claim 1, wherein said polypeptide comprises protein Z Gla domain plus prothrombin Kringle domain.

28. The method of claim 1, wherein said polypeptide comprises Factor VII Gla domain.

29. The method of claim 1, wherein said polypeptide comprises Factor VII Gla domain plus prothrombin Kringle domain.

30. The method of claim 1, wherein said polypeptide further comprises an antibody Fc region.

31. The use of an isolated polypeptide comprising a gamma-carboxyglutamic-acid (Gla) domain and lacking a protease or hormone-binding domain, wherein said polypeptide is linked to a therapeutic payload, in the manufacture of a medicament for the treatment of cancer.

32. The use of claim 31, wherein said therapeutic payload is a chemotherapeutic, a radiotheraputic or a toxin.

33. The use of claim 31, where said cancer is breast cancer, brain cancer, stomach cancer, lung cancer, prostate cancer, ovarian cancer, testicular cancer, colon cancer, skin cancer, rectal cancer, cervical cancer, uterine cancer, liver cancer, pancreatic cancer, head & neck cancer or esophageal cancer.

34. The use of an isolated polypeptide comprising a gamma-carboxyglutamic-acid (Gla) domain and lacking a protease or hormone-binding domain, wherein said polypeptide is linked to an anti-viral agent, in the manufacture of a medicament for the treatment of a viral disease.

35. The use of claim 34, wherein said viral disease is influenza, human immunodeficiency virus, dengue virus, West Nile virus, smallpox virus, respiratory syncytial virus, Korean hemorrhagic fever virus, chickenpox, varicella zoster virus, herpes simplex virus 1 or 2, Epstein-Barr virus, Marburg virus, hantavirus, yellow fever virus, hepatitis A, B, C or E, Ebola virus, human papilloma virus, rhinovirus, Coxsackie virus, polio virus, measles virus, rubella virus, rabies virus, Newcastle disease virus, rotavirus, HTLV-1 and -2.